Kangyuan Pharmaceutical disclosed the semi -annual report of 2022, achieving revenue of 2.097 billion yuan
Author:Capital state Time:2022.08.01
On August 1, 2022, the A -share listed company Kangyuan Pharmaceutical (code: 600557.SH) released the 2022 semi -annual performance report.
From January 1, 2022-June 30, 2022, the company achieved operating income of 2.097 billion yuan, an increase of 18.54%year-on-year, and net profit was 211 million yuan, a year-on-year increase of 32.35%, and the basic earnings per share were 0.37 yuan.
The company's industry is Chinese medicine.
During the company's reporting period, the total assets at the end of the period were 6.02 billion yuan, operating profit was 257 million yuan, accounts receivable was 760 million yuan, and the net cash flow generated by operating activities was 375 million yuan.Cash is 2312 billion yuan.
Kangyuan Pharmaceutical, the company's full name, Jiangsu Kangyuan Pharmaceutical Co., Ltd., was established on May 08, 1996. The current general manager Yang Yongchun, the main business is the research and development, production and sales of drugs.
- END -
Rural Revitalization ｜ Hunan Chenzhou: "Berry" lives well in Wushan
Luzhou Daily All -Media Reporter Tang Sisi Chen ZhihanSpeaking of Wushan Village, Huatang Town, Beihu District, Luzhou City, I always unconsciously reflect on the sweet and delicious strawberries in t
Endeming the new journey to build a new era · Da Meimei Frontier ｜ Behind the "paid vacation" in Inner Mongolia 100 acres of grassland
